Start here
The easy version says Lilly is winning and Novo is losing. The better read is messier. Novo still has the first oral obesity GLP-1 in the market, and the early prescription count is real. Lilly has the cleaner habit design, the stronger injectable engine, and a pipeline investors trust more.
The pill fight is really a daily-life fight. One medicine asks for an empty stomach and a wait before food or coffee. The other can be taken any time of day, without food or water rules. On paper, clinical weight loss carries the headline. In real life, the morning routine gets a vote.
Novo still knows this disease area deeply. Lilly is a giant company too, with factories, regulators, lawsuits, price pressure, and supply limits of its own. Lilly has momentum. Novo has proof people will actually pick up the pill.
So the read changes. Lilly has not finished Novo's lunch. Lilly is forcing Novo to eat faster, cheaper, and in public.
Eli Lilly
Lilly has the cleaner patient path.
Mounjaro and Zepbound turned Lilly into the company everybody has to price against. Foundayo adds a different kind of pressure. The pill may not beat Novo on every clinical headline, but it removes a small daily tax. No empty-stomach rule. No 30-minute wait. For a medicine people may take for years, small friction can become the whole product.
Novo Nordisk
Novo still has the first pill people are actually filling.
Wegovy pill gave Novo a real counterpunch after a rough stretch. New CEO, restructuring, layoffs, and Lilly pressure all hit at once. The pill gives Novo a live lane back into the fight. The question is whether the company can turn an early launch into a durable habit before Lilly's easier routine catches up.
The scoreboard
- Lilly: Q1 2026 revenue reached $19.8B, up 56%. The GLP-1 machine is no side business.
- Lilly: Mounjaro brought in $8.7B in Q1 2026, and Zepbound brought in $4.16B. That is the cash engine under the pill story.
- Lilly: Foundayo won FDA approval as an oral GLP-1 pill with no food or water restrictions. That is product design, not only chemistry.
- Novo: 2025 sales reached DKK 309.1B, up 10% at constant exchange rates. This is a pressured company, not a weak one.
- Novo: Wegovy pill passed 3 million prescriptions in just over five months, with most new starts coming from people new to GLP-1 therapy. The launch has teeth.
- Novo: the company is carrying a leadership reset and 9,000 planned job cuts while trying to defend its best market. That is a hard turn at speed.
Still working
- Lilly has the stronger growth engine and a broader obesity pipeline behind the pill.
- Foundayo fits a normal morning better than a pill with fasting rules.
- Mounjaro and Zepbound give Lilly commercial muscle while the oral market opens.
- Novo has real obesity trust, deep semaglutide knowledge, and first-mover proof in oral Wegovy.
- Wegovy pill is bringing new GLP-1 patients into the market, not only switching old ones.
- Novo still has global reach, manufacturing depth, and a direct line to prescribers.
Still stuck
- Lilly has to scale a new pill while the rest of its GLP-1 demand is already stretching capacity.
- Lower realized prices are already showing up in Lilly's numbers. Volume is winning, but price is fighting back.
- Foundayo still has to build trust against a known molecule with a head start.
- Novo has the harder routine. The empty-stomach rule and wait time create daily drag.
- The leadership reset and layoffs put Novo in repair mode while the market is moving faster.
- CagriSema and other next-generation bets have to restore confidence after Lilly changed the comparison set.
Bottom line
At work today, pick one product or process people use repeatedly and map the first five minutes around it. The sale may happen in the pitch, but retention happens in the routine.
The move is simple: remove one tiny daily tax before adding another feature. In long-use markets, the easier habit often beats the louder claim.